Table 2. A.

Spearman Correlations with the cetuximab sensitivity (CTX-S) score

All CRC tumors/cell lines (regardless of RAS status)
Spearman Corr. with CTX-S score	Moffitt CRCs (n=458)*		TCGA CRCs (n=624)		Marisa et al (2013) CRCs (n=566)		Khambata-Ford et al (2007) CRCs (n=80)		Medico et al (2015) CRC cell lines (n=147)
Gene expression/Signature scores	r	p value	r	p value	r	p value	r	p value	r	p value
EREG	0.562	<0.0001	0.592	<0.0001	0.655	<0.0001	0.711	<0.0001	0.266	0.001
AREG	0.463	<0.0001	0.469	<0.0001	0.542	<0.0001	0.624	<0.0001	−0.173	0.036
18-gene RAS pathway score	−0.361	<0.0001	−0.209	<0.0001	−0.491	<0.0001	0.123	0.277	−0.106	0.201
64-gene Wnt pathway score	0.069	0.140	0.023	0.573	0.036	0.655	0.276	0.013	0.311	0.0001
24-gene Wnt pathway score	0.553	<0.0001	0.457	<0.0001	0.558	<0.0001	0.666	<0.0001	0.488	<0.0001

Note

^*Of Moffitt 468 CRCs, 10 samples lacking appropriate gene probe values for some signature scores were excluded from correlation analysis.